Transaction · 0001729510-26-000006

Li Zhen

Li Zhen, PRES, reported a transaction classified as grant at ADARx Pharmaceuticals, Inc. involving 1024152.000000 shares for an estimated $0.00. Reported holdings after the transaction were 1024152.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

grantSEC transaction code APRES
ADRXADARx Pharmaceuticals, Inc.
Filing timeSep 28
Trade dateSep 24, 2026
Filing · SECView on SEC
InsiderProfile
% of reported position tradedUnavailableNot calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
—
Pre-filing
1mo ago1w ago1d ago
Returns since
7d30d90d180d1y

ADRX price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
ADRX since 2026-09-28Filed yesterday · 1 day of post-filing data
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Derivative
Type
grant
Code A
Identifier
0001729510-26-000006
Employee Stock Option (right to buy)
Transaction date
Sep 24, 2026
Filed Sep 28, 2026, 08:30 PM · 4d delay
Shares
1.02M sh
$0.00 per share
Estimated value
$0
Computed from shares × price
Holdings after
1.02M sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Derivative Transaction Direct Ownership Large Holdings Increase
-10score
Filing-only score

-10

Compact filing score computed from stored Form 4 facts. Version v1.

Mixed or weak signal

This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

President and CEO

Officer YesDirector Yes10% YesOther No
Footnotes & amended
  1. F1

    1/4th of the total shares vest and become exercisable on September 24, 2027 and the remaining shares vest and become exercisable in equal quarterly installments thereafter over a three-year period, su…

Original filing · 0001729510-26-000006
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

ADRX